Testicular LymphomaNCT06964841
PRIMARY TESTICULAR LYMPHOMA
An observational study of Testicular Lymphoma, run by Instituto Mexicano del Seguro Social at 1 site in Mexico.
Trial summary
742 / 5.000 A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent. The patient presented with an enlarged right testicle that had been present for 1 month. Read more about this study
- Who is it for?
- Any age, men only
- Conditions the study is for
- Testicular Lymphoma
- How many people
- 1 participants
- Where
- 1 siteMexico
- Study dates
- 1 Jan 2025to 29 Mar 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- Men only
- No healthy volunteers
- Child, Adult, Older adult
Study population: 57 year old male with testicular lymphoma
Who may be able to join
- Patient with testicular lymphoma
Who cannot join
- Patient without testicular lymphoma
Trial locations and contacts
1 site in 1 country.
About this study
Official title: PRIMARY TESTICULAR LYMPHOMA WITH EXTRA-NODAL STOMACH AFFECTATION
742 / 5.000 A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.
The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, nontender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.
The left testicle was normal.
He underwent radical orchiectomy, which revealed renal testicular lymphoma.
Read the detailed description
A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.
The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, non-tender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.
The left testicle was normal.
He underwent radical orchiectomy, which revealed renal-testicular lymphoma.
On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.
He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a 6 cm bleeding gastric ulcer. A biopsy was taken and a diffuse B-cell lymphoma was detected.
He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.
On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.
He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.
The patient continued to have melena and grade IV anemia. He was referred to pathology, where he was found to have OMS. He showed no improvement despite blood transfusions. He died. Immunohistochemistry for both testicular lesions and on the third postoperative day.
- Conditions
- Testicular Lymphoma
- Keywords
- testis, lymphoma, nodal, stomach
- Medical subject headings
- Lymphoma
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Describe the mortality in primary testicular lymphoma
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 May 2025
- Study start1 Jan 2025
- Primary completion28 Mar 2025
- Study completion29 Mar 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Testicular LymphomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Retrospective
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Instituto Mexicano del Seguro Social
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Huber Díaz Fuentes, Instituto Mexicano del Seguro Social
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06964841
- Sponsor's protocol ID
- 982121
- Status last verified
- May 2025
- First submitted
- 1 May 2025
- Last updated
- 9 May 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: anyone who ask via e-mail
Publications
Motyckova M, Vosahlova V, Belada D, Simkovic M, Zak P. [Primary testicular lymphoma]. Vnitr Lek. 2017 Summer;63(6):415-422. Czech.
PubMed 28840738
Study at a glance
From the registry record, last updated by the sponsor on 9 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- PRIMARY TESTICULAR LYMPHOMA WITH EXTRA-NODAL STOMACH AFFECTATION
- ClinicalTrials.gov ID
- NCT06964841
- Acronym / sponsor ID
- 982121
- Conditions
- Testicular Lymphoma
- Keywords
- testis, lymphoma, nodal, stomach
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Instituto Mexicano del Seguro SocialOther government
- Study start
- 1 Jan 2025 (actual)
- Primary completion
- 28 Mar 2025 (actual)
- Study completion
- 29 Mar 2025 (actual)
- First posted
- 9 May 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
742 / 5.000 A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.
The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, nontender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.
The left testicle was normal.
He underwent radical orchiectomy, which revealed renal testicular lymphoma.
Detailed description
A 57-year-old male: Denies chronic degenerative, allergic, traumatic, transfusional, or surgical complications. He denies a family history of testicular cancer or abnormalities in testicular descent.
The patient presented with an enlarged right testicle that had been present for 1 month. He saw his family doctor, who prescribed antibiotic and analgesic treatment, without improvement, and was referred to our service. Upon examination, the right testicle was palpable, non-tender, slightly enlarged, indurated, with nodulations measuring 0.5 cm in diameter, and free spermatozoa.
The left testicle was normal.
He underwent radical orchiectomy, which revealed renal-testicular lymphoma.
On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.
He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a 6 cm bleeding gastric ulcer. A biopsy was taken and a diffuse B-cell lymphoma was detected.
He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.
On the first postoperative day, the patient began to have stools with malignant cells and discontinuous invasion of the umbilical cord.
He was evaluated by the Gastroenterology department, who indicated the performance of an endoscopy, which revealed a large lesion.
The patient continued to have melena and grade IV anemia. He was referred to pathology, where he was found to have OMS. He showed no improvement despite blood transfusions. He died. Immunohistochemistry for both testicular lesions and on the third postoperative day.
Study design
- Observational model
- Case only
- Time perspective
- Retrospective
Who may qualify
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- 57 year old male with testicular lymphoma
Key inclusion criteria (1 listed)
- Patient with testicular lymphoma
Key exclusion criteria (1 listed)
- Patient without testicular lymphoma
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Mortality
Time frame: 3 months
Describe the mortality in primary testicular lymphoma
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 May 2025.
- Results publication: PubMed 28840738Motyckova M, Vosahlova V, Belada D, Simkovic M, Zak P. [Primary testicular lymphoma]. Vnitr Lek. 2017 Summer;63(6):415-422. Czech.
- Individual participant dataSharing planned: Yes. anyone who ask via e-mail
Related trials for Testicular Lymphoma
Active, not recruitingObservational study
Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8
RecruitingPhase 3
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma
Recruiting
The TASTY-steering Study
Metastatic Triple Negative Breast Cancer, Metastatic Testicular Cancer
Active, not recruitingPhase 1
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
Adult Grade III Lymphomatoid Granulomatosis, Cutaneous B-cell Non-Hodgkin Lymphoma
Recruiting
Digital Peer Navigation for Adolescents and Young Adults With Cancer
Lymphoma, Breast Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Testicular Lymphoma, run by Instituto Mexicano del Seguro Social at 1 site in Mexico.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 9 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Mexico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06964841, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 May 2025.